Valuation: Adimmune Corporation

Market Cap 7.54B 237M 208M 197M 179M 336M 22.76B 338M 2.35B 912M 11.63B 891M 872M 37.36B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 7.54B 237M 208M 197M 179M 336M 22.76B 338M 2.35B 912M 11.63B 891M 872M 37.36B EV / Sales 2026 *
4.98x
EV / Sales 2027 * 4.5x
Free-Float
70.19%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week+0.56%
Current month+0.85%
1 month+1.13%
3 months+4.68%
6 months-3.76%
Current year-5.54%
1 week 17.55
Extreme 17.55
17.95
1 month 17.05
Extreme 17.05
18.2
Current year 16.4
Extreme 16.4
21.5
1 year 16.4
Extreme 16.4
22.5
3 years 15.9
Extreme 15.9
36.6
5 years 15.9
Extreme 15.9
52.4
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 19/06/2019
Director of Finance/CFO - 31/12/2020
Chief Tech/Sci/R&D Officer - 25/01/2022
Director TitleAgeSince
Director/Board Member - 19/06/2019
Director/Board Member - 14/08/2011
Director/Board Member - 28/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%+0.56%-4.28%-47.81% 237M
-1.00%+0.41%+41.86%-5.58% 78.69B
+2.08%+29.11%+708.13%+102.59% 79.4B
-1.21%+0.77%-10.63%-30.06% 59.52B
-1.80%-2.29%-13.07%+28.02% 46.53B
+1.18%+3.03%+9.11%+169.01% 46.58B
+0.55%+5.61%+67.76%-10.75% 33.63B
-0.44%-1.13%+51.71%+110.88% 25.11B
-0.10%+3.21%+4.89%+155.64% 22.13B
+0.05%-2.42%+57.59%+97.38% 15.31B
Average -0.29%+3.70%+91.31%+56.93% 40.71B
Weighted average by Cap. -0.51%+6.45%+155.40%+55.12%

Financials

2026 *2027 *
Net sales 1.52B 47.67M 41.83M 39.51M 36.01M 67.4M 4.57B 67.88M 473M 183M 2.33B 179M 175M 7.5B 1.68B 52.77M 46.31M 43.74M 39.86M 74.61M 5.06B 75.14M 523M 203M 2.58B 198M 194M 8.3B
Net income - -
Net Debt - -
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
24/09/26 NT$17.90 +0.28% 727,893
23/09/26 NT$17.85 0.00% 460,065
22/09/26 NT$17.85 +0.85% 730,682
21/09/26 NT$17.70 -0.56% 359,673
18/09/26 NT$17.80 +0.28% 805,993
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
17.90TWD
Average target price
21.00TWD
Spread / Average Target
+17.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock